Results 221 to 230 of about 90,516 (299)

Spider-MS: an individualized polyhedral prediction of multiple sclerosis prognosis. [PDF]

open access: yesBrain
Tur C   +31 more
europepmc   +1 more source

Consensus‐based follow‐up and treatment registry for GNAO1‐associated disorder

open access: yesDevelopmental Medicine &Child Neurology, Volume 68, Issue 9, Page 1316-1324, September 2026.
This original article is commented on by Domínguez‐Carral and Ortigoza‐Escobar on pages 1182–1183 of this issue. Abstract Aim To establish consensus‐based recommendations on relevant domains of functioning and assessment instruments for an GNAO1‐associated disorder follow‐up and treatment registry.
Larissa R. Heideman   +9 more
wiley   +1 more source

POEMS syndrome: A case report. [PDF]

open access: yesRadiol Case Rep
Esfahani MM, Shafieioun S, Zahedimehr H.
europepmc   +1 more source

Collaborative practice to support community‐based physical activity for young people with childhood‐onset physical disability: A scoping review

open access: yesDevelopmental Medicine &Child Neurology, Volume 68, Issue 9, Page 1195-1206, September 2026.
This scoping review highlights that collaboration between healthcare and physical activity providers to support community physical activity participation for young people with childhood‐onset physical disability is limited. Collaboration strategies to support community physical activity lack sufficient detail for replication.
Karen Brady   +5 more
wiley   +1 more source

Concussion is associated with multiple sclerosis if it occurs before infectious mononucleosis. [PDF]

open access: yesBrain Commun
Montgomery S   +5 more
europepmc   +1 more source

Practical Guidance on Initiating and Switching Targeted Immunotherapies in Generalised Myasthenia Gravis: A German–Austrian Expert Opinion Paper

open access: yesEuropean Journal of Neurology, Volume 33, Issue 9, September 2026.
ABSTRACT Background The therapeutic landscape of generalised myasthenia gravis (gMG) has evolved substantially with the approval of targeted immunotherapies, including complement C5 inhibitors (C5‐I) and neonatal Fc receptor inhibitors (FcRn‐I). While pivotal trials have demonstrated marked efficacy in defined subgroups, real‐world experience reveals ...
Andreas Meisel   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy